Advancing the Development, from Research to Market, of Effective Therapies for RAS-Mutant Cancers Ranging from G12C to Q61 Modalities to Attain Targeted Drugs for Patients in Need
5th Annual RAS-Targeted Drug Development Summit
Personalizing Medicine Via Targeting Oncogenic RAS for Cancer
With the approval of the second-ever KRAS G12C inhibitor, the field can once again celebrate irrevocable proof that RAS is druggable! However, with so many KRAS G12C drugs in clinic, the field is now turning its eyes to the next generation of RAS therapies, specifically those that can target more mutations, more RAS isoforms, and more indications.
And so, the 5th RAS-Targeted Drug Development Summit arrives as the only industry-dedicated, end-to-end forum to accelerate your best-in-class RAS therapies from conception through to commercialization.
Set to unite 150+ key leaders in biopharma and academia in Boston this September, we are eager to tackle emerging resistance mechanisms, assess promising combination approaches and explore novel RAS therapies.
Hear from 45+ expert speakers across 3 jam-packed days of data-driven presentations, interactive workshops, and panel discussions. This is your one-stop shop to hear the hottest clinical updates, better target non-G12C mutations, validate novel targets in the RAS pathway, and experience the next generation of RAS-targeted drugs.
World-Class Speaker Faculty Includes:
Companies on the Program Include:
Hear What Our Past Attendees Have to Say:
Proud to Partner With:
Other Events in the Small Molecules & TPD World Series
